Actively Recruiting
Study of NNC0487-0111 Injections Once Weekly for Adults with Overweight or Obesity and Type 2 Diabetes
Led by Novo Nordisk A/S · Updated on 2026-09-30
630
Participants Needed
74
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of NNC0487-0111 for treating adults with excess body weight and type 2 diabetes. The study compares four different doses of NNC0487-0111 with a placebo, which contains no active medicine. Participants receive these treatments as weekly injections under the skin, and their group assignment is decided randomly. Participants are assigned to one of five groups four groups receive different dose levels of NNC0487-0111, and one group receives a placebo. All participants also follow a reduced-calorie diet and increase their physical activity. The injections are administered once weekly using a pre-filled pen injector to the thigh, abdomen, or upper arm. Treatment continues for 84 weeks, with ongoing monitoring. Throughout the study, participants will have their body weight, waist circumference, blood sugar control HbA1c, blood pressure, cholesterol levels, and quality of life assessed at the start and at week 84. Safety is monitored by tracking adverse events and episodes of low blood sugar up to week 88. The study lasts for about 84 weeks of treatment plus safety follow-up, and participants may undergo laboratory tests and physical exams during this time.
CONDITIONS
Brief Title
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Research Team
N
Novo Nordisk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here